CanSino Biologics Secures NMPA Approval to Expand Menhycia MCV4 Vaccine to Children Up to 6 Years Old
Key Insights
CanSino Biologics (search) received NMPA approval to expand its Menhycia MCV4 vaccine age range from 3 months-3 years to 3 months-6 years old in China.
The expanded approval addresses a gap in multivalent conjugate vaccine options for children over age three in the domestic market.
CanSino forecasts 2025 revenue of RMB 1.04-1.08 billion with 22.88%-27.61% year-over-year growth, marking a return to profitability.
CanSino Biologics (search) Inc. (688185.SH/06185.HK) has received approval from China's National Medical Products Administration (search) (NMPA) to expand the age indication for its Menhycia MCV4 vaccine, extending coverage from children aged 3 months to 3 years old to children aged 3 months to 6 years old (83 months). The supplemental drug application approval was announced on February 24, 2026.
Addressing Market Gap in Pediatric Vaccination
The expanded approval addresses a significant gap in China's pediatric vaccination landscape. For a long time, multivalent conjugate vaccine options for children over age three have been relatively limited in the domestic market. Under China's current national immunization schedule, the final pre-school dose of meningococcal vaccination is administered at six years of age, making this age expansion particularly relevant for comprehensive pediatric protection.
Menhycia represents China's first domestically developed quadrivalent meningococcal conjugate vaccine, providing CanSino with a first-mover advantage in this therapeutic area. The Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (search) (CRM197) offers protection against meningococcal meningitis (search), a serious bacterial infection.
Commercial Impact and Financial Performance
The broader eligible population is expected to unlock significant commercialization prospects for Menhycia and strengthen the product's strategic rollout in international markets. CanSino recently issued its Results Forecast for 2025, projecting total revenue of RMB 1.04-1.08 billion, representing a year-on-year increase of 22.88% to 27.61%. The company expects net profit attributable to shareholders of RMB 24.5-29.0 million, marking a return to profitability.
The company noted that Menhycia continues to drive sustained revenue growth under its innovation-led commercialization strategy, demonstrating that CanSino is now reaping the commercial benefits of its early investments in vaccine innovation. The announcement indicates ongoing success in increasing market share, which may be indicative of sustained revenue trends and improved profitability.
Strategic Positioning and Future Outlook
As the first mover in China with an MCV4 vaccine, CanSino enjoys a competitive edge in providing superior solutions for preventing meningococcal meningitis (search) among children under 6 years old. The age expansion is expected to further strengthen CanSino's competitive position while providing new momentum for sustainable growth.
Leveraging its proprietary platform, first-mover advantages, and accelerating global expansion, the company is well-positioned to enter a new phase of long-term growth as product coverage broadens and international commercialization advances. The regulatory milestone represents a major development likely to positively influence the company's market position and revenue potential by enabling access to a significantly larger pediatric population.